SSH Salt sensitive hypertension T1/2 Estimated terminal half-life TEAE treatment emergent adverse event TIA transient ischaemic attack Tmax Time to maximal drug concentration TR tricuspid regurgitation ULN upper limit of normal Apparent volume of distribution during terminal phase (associated Vz/F with corrected for bioavailability) λZ WBC white blood cells WHO World Health Organisation
SSH Salt sensitive hypertension T1/2 Estimated terminal half-life TEAE treatment emergent adverse event TIA transient ischaemic attack Tmax Time to maximal drug concentration TR tricuspid regurgitation ULN upper limit of normal Vz/F Apparent volume of distribution during terminal phase (associated with λZ corrected for bioavailability) WBC white blood cells WHO World Health Organisation
auspar-sacubitril-valsartan-salt-complex-160923-cer.docx